Tirzepatide vs. Semaglutide: How the Two GLP-1s Compare

The headline: same delivery, same weekly cadence, similar side effects — but a different mechanism, and tirzepatide has shown larger average weight loss in trials. Now the detail that actually helps you decide.

Both medications mimic GLP-1, a gut hormone your body releases after eating that signals fullness, slows stomach emptying, and reduces appetite. That's the whole mechanism behind the reduced hunger people describe.

The difference is that tirzepatide adds a second target: GIP, another gut hormone involved in how your body handles food and energy. So semaglutide pulls one lever; tirzepatide pulls two. The leading theory is that engaging both pathways is why tirzepatide has tended to produce greater weight loss in studies — though “more receptors” doesn't automatically mean “better for you,” which is the part a physician weighs.

This is where the honest numbers matter. In the pivotal trials:

• Semaglutide (in the STEP-1 trial) produced an average of about 15% body-weight reduction over 68 weeks (Wilding et al., 2021).
• Tirzepatide (in the SURMOUNT-1 trial) produced up to about 20%+ average reduction over 72 weeks at the highest dose (Jastreboff et al., 2022).

Two honest caveats you should hold onto. First, these are averages from controlled trials paired with lifestyle support — individual results vary a great deal, and they are not a guarantee of what any one person will experience. Second, these trials studied the FDA-approved brand products. That matters for the compounded-versus-brand distinction below.

So on the evidence, tirzepatide tends to deliver more weight loss on average. That's a real point in its favor — but it's one input, not the whole decision.

Both medications share a similar side-effect profile, and it's mostly gastrointestinal: nausea is the most common, along with things like diarrhea, constipation, and reduced appetite (which is partly the point). These tend to be most noticeable when starting or increasing the dose and often ease over time, which is why both are titrated up slowly.

Both also carry the same categories of more serious precautions and contraindications, which is exactly why neither should be started without a physician evaluating your history first. “Which has fewer side effects” isn't a clean win for either — they're comparable, and how you tolerate one specifically is individual.

Honestly, that's not a question an article can answer, and be skeptical of any page that picks one for you sight unseen.

Tirzepatide's larger average weight loss makes it appealing, but the right choice genuinely depends on your health history, how you tolerate the medication, other conditions and medications, and a physician's judgment. Some people do very well on semaglutide; some tolerate one better than the other; candidacy and safety screening come first for both. The useful takeaway isn't “tirzepatide wins” — it's “these are two strong, closely related options, and which fits you is a medical decision.”

Here's something most comparison articles skip, and it matters. Semaglutide and tirzepatide each exist as FDA-approved brand-name products (Ozempic® and Wegovy® for semaglutide; Mounjaro® and Zepbound® for tirzepatide). They also exist as compounded versions prepared by pharmacies.

Protocol MD provides physician-prescribed, compounded semaglutide and tirzepatide. Being direct about what that means: compounded medications are not FDA-approved, and a compounded version is not the same product as the brand-name medication that was studied in the trials above — even though it contains the same active ingredient. We think it's important to state that plainly rather than blur the line. Whether a compounded option is appropriate for you is part of the conversation with a prescribing physician.

If you're considering either, the process is the same and it starts with an evaluation: a US-licensed physician reviews your intake and history and determines whether semaglutide, tirzepatide, or neither is appropriate for you — no medication is prescribed without that. It's physician-prescribed, not a marketplace, and candidacy and safety screening come first. If you want to see whether you're a fit, start with a quick evaluation.

So, tirzepatide vs. semaglutide? They're close relatives — both GLP-1-based, both weekly, both working by reducing appetite — with one key mechanistic difference (tirzepatide's dual GIP/GLP-1 action) and a real evidence difference (greater average weight loss for tirzepatide in trials). But averages aren't individuals, side effects are comparable, and neither is right for everyone. The genuinely useful answer isn't a winner — it's that both are strong options, and which one fits you is a decision to make with a licensed physician after an evaluation, not from a comparison chart.